

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Hong Kong Life Sciences and Technologies Group Limited

香港生命科學技術集團有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 8085)

**COMPLETION OF DISCLOSEABLE TRANSACTION
IN RELATION TO THE ACQUISITION OF ENTIRE ISSUED
SHARE CAPITAL OF
HONORBASE INTERNATIONAL LIMITED**

Reference is made to the announcement of Hong Kong Life Sciences and Technologies Group Limited (the “**Company**”) dated 31 May 2017 (the “**Announcement**”) in relation to the acquisition of entire issued share capital of Honorbase International Limited. Unless otherwise defined, capitalized terms used herein shall bear the same meanings as defined in the Announcement.

The Board is pleased to announce that all the conditions precedent to the Agreement have been fulfilled and Completion took place on 7 June 2017 in accordance with the terms and conditions of the Agreement.

Upon Completion, the Target Company has become an indirect wholly-owned subsidiary of the Company and financial results of the Target Company will be consolidated to financial results of the Group.

By order of the Board

Hong Kong Life Sciences and Technologies Group Limited

Lu Zhiqiang

Executive Director and Chief Executive Officer

Hong Kong, 7 June 2017

As at the date of this announcement, the Board comprises (i) five executive Directors, namely, Mr. David Lin Kao Kun, Mr. Lu Zhiqiang, Mr. Chui Kwong Kau, Mr. Jiang Hongqing and Ms. Li Mei; (ii) one non-executive Director, namely Ms. Lam Kuo; and (iii) three independent non-executive Directors, namely Mr. Hung Yat Ming, Mr. Chan Yun Hing, and Mr. Gui Qiangfang.

This announcement, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the GEM Listing Rules for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that to the best of their knowledge and belief the information contained in this announcement is accurate and complete in all material respects and not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this announcement misleading.

This announcement will remain on the “Latest Company Announcements” page of the GEM website at <http://www.hkgem.com> for a minimum period of seven days from the date of its publication and on the Company’s website at <http://www.hklifesciences.com>.